A mobile medical app that helps people decide how much insulin to take. Humanising diabetes technology.
- £1.94M raised so far in grants and angel funding
- 76% of Quin users feel better about living with diabetes
- Selected by Apple for insider access to engineers and execs
- Founder is a robotics engineer living with diabetes for 26 years
We are humanising diabetes technology for better health outcomes and quality of life.
An estimated 92% of nearly 40 million people with insulin-treated diabetes do not achieve recommended medical targets. They’re 2-3 times more likely to have anxiety and depression. Why? The science of diabetes is incomplete, so people fill the gaps with their own trial and error and diabetes technology.
Quin is a mobile medical app that combines daily life experience with data from diabetes devices and phones to help people decide how much insulin to take and when. We are structuring this data to reveal insights into the causes behind fluctuations in blood glucose and expand diabetes science.
In the past 2 years, 100+ people who take insulin have been guiding our R&D. 76% of Quin users feel better about living with diabetes and 35% have improved their HbA1c – healthcare’s target measure. We now want to launch Quin and help more people achieve the target with a better quality of life.
Our founder, Isabella, has been living with type 1 diabetes for 26 years. Quin’s vision was born from her love for making machines do things people don’t want to do while making hundreds of diabetes decisions a day.
At diagnosis, people are given general medical formulas to calculate how much insulin to take for what they eat. Those formulas don’t accurately reflect what goes on in their body. So, people use trial and error to personalise them for everything they do: eating, moving, working, sleeping – all aspects of their daily life.
The latest diabetes technology seeks to refine the general medical formulas to personalise insulin dosing. But if they don’t work for people, they won’t work for technology either.
Quin takes a different approach. It’s based on the principle that your past insulin-dosing decisions – not medical formulas – are the most reliable basis for your future insulin-dosing decisions. It’s human-first, and our early data shows it works.
Substantial accomplishments to date
76% of Quin users feel better about living with diabetes, and 35% have improved their HbA1c – healthcare’s target measure.
Apple has granted us insider access to their engineers and executives who are helping us get Quin to market.
Our proven multi-disciplinary team of 12 is highly skilled in engineering, design, product, and marketing, and we have an extensive network of committed professional advisors. Our app has a class I CE Mark, and we have 2 patents pending. We have raised £1.94M in grants and angel funding.
Forbes recently featured Quin: How This App Could Transform Diabetes Management For Millions Across The World https://www.forbes.com/sites/nicholasfearn/2020...
Innovate UK and UK Research and Innovation have showcased Quin as a leading-edge healthcare innovation: https://www.gov.uk/government/case-studies/diab...
Our business model will generate revenue from both business-to-consumer (B2C) and business-to-business (B2B) opportunities.
The Quin app will be made available to consumers via the Apple app store on a monthly subscription fee basis. Payment will be made either by reimbursement from the healthcare payer/provider or directly out of pocket. Customers will be acquired through inbound digital marketing, distribution partnerships, and healthcare payer/providers.
The global market for diabetes devices, covering glucose monitoring and insulin delivery, was valued at $21.7B in 2017, and is expected to expand to $32.9B in 2025. The global insulin market is predicted to reach $70.6 billion by 2023.
Quin’s data and algorithms will make these drugs and devices much more personalised and effective, and B2B revenue streams will flow from these opportunities in the future.
Use of proceeds
We have a proven team and processes in place to support our research and development, user safety and regulatory compliance needs. We are raising Seedrs funds alongside funds from angel investors to support the launch of the Quin app. Our Seedrs proceeds will go almost exclusively towards:
- Hiring a product designer to enhance the user experience
- Achieving ISO 13485 certification and compliance with new European Medical Device Regulations
- Hiring a marketer and building out our infrastructure and capabilities to acquire and manage thousands of customers after launch
- Developing B2B2C distribution partnerships
- Launching the Quin app in the UK and Europe in late 2020
The Company has one outstanding loan of £100k from ThoughtWorks for software development services. The repayment date for this loan is subject to negotiation but is due to be repaid during the course of the raise. The proceeds of the raise will not be used to repay this loan.